Stockreport

Carisma Therapeutics' solid tumour therapy obtains FDA Fast Track status [Yahoo! Finance]

Carisma Therapeutics, Inc.  (CARM) 
PDF An ex vivo gene-modified autologous chimeric antigen receptor-monocyte cellular therapy, CT-0525 is being analysed in a Phase I clinical trial. The open-label trial i [Read more]